Patents by Inventor Satoshi Komoriya
Satoshi Komoriya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11530211Abstract: It is an object of the present invention to provide a new compound capable of efficiently inducing differentiation from pluripotent stem cells into insulin-producing cells. The object of the present invention is achieved by a compound represented by formula (I): wherein R1, R2, R3, n and A have the same meanings as defined in the description, respectively, or a salt thereof.Type: GrantFiled: January 18, 2019Date of Patent: December 20, 2022Assignee: Daiichi Sankyo Company, LimitedInventors: Toshihiro Kiho, Tatsuya Yano, Satoshi Komoriya, Taisaku Tanaka
-
Publication number: 20210053965Abstract: It is an object of the present invention to provide a new compound capable of efficiently inducing differentiation from pluripotent stem cells into insulin-producing cells. The object of the present invention is achieved by a compound represented by formula (I): wherein R1, R2, R3, n and A have the same meanings as defined in the description, respectively, or a salt thereof.Type: ApplicationFiled: January 18, 2019Publication date: February 25, 2021Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Toshihiro Kiho, Tatsuya Yano, Satoshi Komoriya, Taisaku Tanaka
-
Patent number: 10808006Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.Type: GrantFiled: February 15, 2019Date of Patent: October 20, 2020Assignee: Daiichi Sankyo Company, LimitedInventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki
-
Publication number: 20190233466Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.Type: ApplicationFiled: February 15, 2019Publication date: August 1, 2019Applicant: Daiichi Sankyo Company, LimitedInventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki
-
Patent number: 10253060Abstract: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway.Type: GrantFiled: September 14, 2017Date of Patent: April 9, 2019Assignee: Daiichi Sankyo Company, LimitedInventors: Satoshi Komoriya, Yasuhiro Nakagami, Emiko Hatano, Takashi Ohnuki, Kayoko Masuda, Mayumi Iizuka, Yasunori Ono
-
Patent number: 10208082Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.Type: GrantFiled: September 9, 2015Date of Patent: February 19, 2019Assignee: Daiichi Sankyo Company, LimitedInventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki
-
Publication number: 20180016298Abstract: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway.Type: ApplicationFiled: September 14, 2017Publication date: January 18, 2018Applicant: Daiichi Sankyo Company, LimitedInventors: Satoshi Komoriya, Yasuhiro Nakagami, Emiko Hatano, Takashi Ohnuki, Kayoko Masuda, Mayumi Iizuka, Yasunori Ono
-
Patent number: 9796752Abstract: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway.Type: GrantFiled: March 18, 2014Date of Patent: October 24, 2017Assignee: Daiichi Sankyo Company, LimitedInventors: Satoshi Komoriya, Yasuhiro Nakagami, Emiko Hatano, Takashi Ohnuki, Kayoko Masuda, Mayumi Iizuka, Yasunori Ono
-
Publication number: 20170260228Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.Type: ApplicationFiled: September 9, 2015Publication date: September 14, 2017Applicant: Daiichi Sankyo Company, LimitedInventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki
-
Publication number: 20160297849Abstract: It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway.Type: ApplicationFiled: March 18, 2014Publication date: October 13, 2016Inventors: Satoshi Komoriya, Yasuhiro Nakagami, Emiko Hatano, Takashi Ohnuki, Kayoko Masuda, Mayamu Lizuka, Yasunori Ono
-
Publication number: 20140142096Abstract: A quinolone synthetic antibacterial agent having excellent properties as a medicine is provided, which has strong antibacterial activity not only to Gram-negative bacteria but also to Gram-positive cocci that have low sensitivity to quinolone antibacterial agents, and which exhibits high safety and excellent pharmacokinetics. A compound represented by the formula (I) or a salt thereof, or a hydrate thereof. Specifically, a quinolone derivative of the formula (I) wherein substituents R6 and R7 taken together with the carbon atoms to which they are bonded form a cyclic structure which may contain an oxygen atom as a ring constituent atom, the cyclic structure forming a 5-4, 5-5, or 5-6 fused bicyclic pyrrolidinyl substituent, the substituent being bonded to a quinolone mother skeleton Q containing a pyridobenzoxazine structure.Type: ApplicationFiled: November 19, 2013Publication date: May 22, 2014Applicant: Daiichi Sankyo Company, LimitedInventors: Hisashi Takahashi, Satoshi Komoriya, Takahiro Kitamura, Takashi Odagiri, Hiroaki Inagaki, Toshifumi Tsuda, Kiyoshi Nakayama, Makoto Takemura, Kenichi Yoshida, Rie Miyauchi, Masatoshi Nagamochi
-
Patent number: 8618094Abstract: A quinolone synthetic antibacterial agent having excellent properties as a medicine is provided, which has strong antibacterial activity not only to Gram-negative bacteria but also to Gram-positive cocci that have low sensitivity to quinolone antibacterial agents, and which exhibits high safety and excellent pharmacokinetics. A compound represented by the formula (I) or a salt thereof, or a hydrate thereof. Specifically, a quinolone derivative of the formula (I) wherein substituents R6 and R7 taken together with the carbon atoms to which they are bonded form a cyclic structure which may contain an oxygen atom as a ring constituent atom, the cyclic structure forming a 5-4, 5-5, or 5-6 fused bicyclic pyrrolidinyl substituent, the substituent being bonded to a quinolone mother skeleton Q containing a pyridobenzoxazine structure.Type: GrantFiled: July 2, 2009Date of Patent: December 31, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Hisashi Takahashi, Satoshi Komoriya, Takahiro Kitamura, Takashi Odagiri, Hiroaki Inagaki, Toshifumi Tsuda, Kiyoshi Nakayama, Makoto Takemura, Kenichi Yoshida, Rie Miyauchi, Masatoshi Nagamochi
-
Patent number: 8476429Abstract: An intermediate for production of a quinolone synthetic antibacterial agent and a therapeutic agent for an infection which exhibit broad spectrum and strong antibacterial activity for both Gram positive and Gram negative bacteria.Type: GrantFiled: April 25, 2012Date of Patent: July 2, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Hisashi Takahashi, Hiroaki Inagaki, Satoshi Komoriya, Makoto Takemura, Rie Miyauchi
-
Publication number: 20130029977Abstract: A quinolone synthetic antibacterial agent having excellent properties as a medicine is provided, which has strong antibacterial activity not only to Gram-negative bacteria but also to Gram-positive cocci that have low sensitivity to quinolone antibacterial agents, and which exhibits high safety and excellent pharmacokinetics. A compound represented by the formula (I) or a salt thereof, or a hydrate thereof. Specifically, a quinolone derivative of the formula (I) wherein substituents R6 and R7 taken together with the carbon atoms to which they are bonded form a cyclic structure which may contain an oxygen atom as a ring constituent atom, the cyclic structure forming a 5-4, 5-5, or 5-6 fused bicyclic pyrrolidinyl substituent, the substituent being bonded to a quinolone mother skeleton Q containing a pyridobenzoxazine structure.Type: ApplicationFiled: July 2, 2009Publication date: January 31, 2013Inventors: Hisashi Takahashi, Satoshi Komoriya, Takahiro Kitamura, Takashi Odagiri, Hiroaki Inagaki, Toshifumi Tsuda, Kiyoshi Nakayama, Makoto Takemura, Kenichi Yoshida, Rie Miyauchi, Masatoshi Nagamochi
-
Publication number: 20120232288Abstract: An intermediate for production of a quinolone synthetic antibacterial agent and a therapeutic agent for an infection which exhibit broad spectrum and strong antibacterial activity for both Gram positive and Gram negative bacteria.Type: ApplicationFiled: April 25, 2012Publication date: September 13, 2012Applicant: Daiichi Pharmaceutical Co., Ltd.Inventors: Hisashi TAKAHASHI, Hiroaki INAGAKI, Satoshi KOMORIYA, Makoto TAKEMURA, Rie MIYAUCHI
-
Patent number: 8211910Abstract: A quinolone synthetic antibacterial agent and a therapeutic agent for an infection which exhibit broad spectrum and strong antibacterial activity for both Gram positive and Gram negative bacteria, and which are also highly safe are provided.Type: GrantFiled: April 13, 2009Date of Patent: July 3, 2012Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Hisashi Takahashi, Hiroaki Inagaki, Satoshi Komoriya, Makoto Takemura, Rie Miyauchi
-
Publication number: 20120108582Abstract: A quinolone synthetic antibacterial agent having excellent properties as a medicine is provided, which has strong antibacterial activity not only to Gram-negative bacteria but also to Gram-positive cocci that have low sensitivity to quinolone antibacterial agents, and which exhibits high safety and excellent pharmacokinetics. A compound represented by the formula (I) or a salt thereof, or a hydrate thereof. Specifically, a quinolone derivative of the formula (I) wherein substituents R6 and R7 taken together with the carbon atoms to which they are bonded form a cyclic structure which may contain an oxygen atom as a ring constituent atom, the cyclic structure forming a 5-4, 5-5, or 5-6 fused bicyclic pyrrolidinyl substituent, the substituent being bonded to a quinolone mother skeleton Q containing a pyridobenzoxazine structure.Type: ApplicationFiled: July 2, 2009Publication date: May 3, 2012Inventors: Hisashi Takahashi, Satoshi Komoriya, Takahiro Kitamura, Takashi Odagiri, Hiroaki Inagaki, Toshifumi Tsuda, Kiyoshi Nakayama, Makoto Takemura, Kenichi Yoshida, Rie Miyauchi, Masatoshi Nagamochi
-
Publication number: 20110312990Abstract: A compound represented by the general formula (1): -Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof.Type: ApplicationFiled: December 13, 2010Publication date: December 22, 2011Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Toshiharu Ohta, Satoshi Komoriya, Toshiharu Yoshino, Kouichi Uoto, Yumi Nakamoto, Hiroyuki Naito, Akiyoshi Mochizuki, Tsutomu Nagata, Hideyuki Kanno, Noriyasu Haginoya, Kenji Yoshikawa, Masatoshi Nagamochi, Syozo Kobayashi, Makoto Ono
-
Publication number: 20110077266Abstract: The present invention relates to diamine compounds which inhibit activated blood coagulation factor X and exhibit an anticoagulant effect and there uses for treating various diseases based on thromboembolism.Type: ApplicationFiled: May 21, 2010Publication date: March 31, 2011Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Toshiharu Ohta, Satoshi Komoriya, Toshiharu Yoshino, Kouichi Uoto, Yumi Nakamoto, Hiroyuki Naito, Akiyoshi Mochizuki, Tsutomu Nagata, Hideyuki Kanno, Noriyasu Haginoya, Kenji Yoshikawa, Masatoshi Nagamochi, Syozo Kobayashi, Makoto Ono
-
Patent number: 7842818Abstract: The present invention provides a method for effectively producing an optically active form of tetrasubstituted-5-azaspiro[2.4]heptane derivative, which serves as a useful production intermediate for quinolonecarboxylic acid antibacterial agents, and intermediates for the derivative. The present invention is directed to a method for producing a compound (VII) according to the following scheme.Type: GrantFiled: September 28, 2006Date of Patent: November 30, 2010Assignee: Daiichi Sankyo Company, LimitedInventors: Hisashi Takahashi, Rie Miyauchi, Yasuyuki Takeda, Kazuo Kanai, Junichi Kuroyanagi, Satoshi Komoriya, Makoto Takemura